A skin-care combination raises a different scientific question from a single ingredient: does the mixture provide a measurable advantage over its individual components? Calling a collection of peptides a stack does not answer that question. An informative study needs the finished mixture, each relevant comparator, a suitable vehicle control and a predefined outcome.

One useful example of controlled cosmetic research is a randomized split-face trial of a palmitoyl pentapeptide formulation. Researchers assessed photoaged facial skin against a matched moisturizer. That is human evidence for the tested formulation and population, not evidence that adding a copper peptide or an injectable research compound improves the result. Robinson et al., topical palmitoyl pentapeptide trial

For combination research, first specify what improvement means. Instrument-measured hydration, an assessor's wrinkle score and a biopsy marker describe different outcomes. They should not be combined into a single claim of skin regeneration. Standardized lighting, blinded image grading and a defined follow-up period can make an appearance endpoint more credible. Irritation and discontinuations belong beside the benefit results.

Formulation also matters. Two ingredients that produce promising signals separately may differ in stability or availability when combined. A laboratory should characterize the finished formulation rather than assume that testing the raw materials settles every question. Claims of synergy require evidence beyond a mixture outperforming an untreated control.

Finally, cosmetic and therapeutic claims have different regulatory implications. FDA distinguishes appearance-focused effects from claims that a product changes skin structure or function. FDA: Wrinkle treatments and other anti-aging products This article does not establish a preferred mixture. Its purpose is to define the evidence a credible comparison would need: a specific formulation, a relevant control, repeatable measurements and a fair account of harms.